Hennion & Walsh Asset Management Inc. Sells 2,808 Shares of Johnson & Johnson (NYSE:JNJ)

Hennion & Walsh Asset Management Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 36,517 shares of the company’s stock after selling 2,808 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Johnson & Johnson were worth $5,918,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Constitution Capital LLC raised its holdings in shares of Johnson & Johnson by 2.0% during the 1st quarter. Constitution Capital LLC now owns 15,677 shares of the company’s stock valued at $2,480,000 after buying an additional 300 shares in the last quarter. RMR Wealth Builders boosted its stake in shares of Johnson & Johnson by 20.8% in the 1st quarter. RMR Wealth Builders now owns 5,394 shares of the company’s stock valued at $853,000 after purchasing an additional 928 shares in the last quarter. Brookstone Capital Management grew its holdings in shares of Johnson & Johnson by 24.9% during the 1st quarter. Brookstone Capital Management now owns 86,516 shares of the company’s stock valued at $13,686,000 after purchasing an additional 17,237 shares during the last quarter. AHL Investment Management Inc. raised its position in Johnson & Johnson by 5.0% in the 1st quarter. AHL Investment Management Inc. now owns 17,322 shares of the company’s stock worth $2,740,000 after purchasing an additional 828 shares during the period. Finally, Future Financial Wealth Managment LLC boosted its position in Johnson & Johnson by 4.6% during the first quarter. Future Financial Wealth Managment LLC now owns 3,612 shares of the company’s stock valued at $571,000 after buying an additional 160 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 1.3 %

Shares of Johnson & Johnson stock opened at $163.67 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company’s fifty day simple moving average is $163.29 and its two-hundred day simple moving average is $154.92. The company has a market cap of $393.90 billion, a P/E ratio of 10.20, a PEG ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the previous year, the business posted $2.66 EPS. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.